NASDAQ: GTHXG1 Therapeutics Inc Stock Ownership - Who owns G1 Therapeutics?
Insider buying vs selling
Have G1 Therapeutics Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| John W. V. Umstead | Chief Financial Officer | 2024-03-18 | 6,547 | $3.02 | $19.75kSell |
| Rajesh Malik | Chief Medical Officer | 2024-02-12 | 28,600 | $4.62 | $132.13kSell |
| Rajesh Malik | Chief Medical Officer | 2024-02-12 | 28,600 | $0.30 | $8.58kBuy |
| Mark Avagliano | Chief Business Officer | 2024-01-04 | 721 | $2.94 | $2.12kSell |
| Rajesh Malik | Chief Medical Officer | 2024-01-04 | 721 | $2.94 | $2.12kSell |
| Terry L. Murdock | Chief Operating Officer | 2024-01-04 | 721 | $2.94 | $2.12kSell |
| John W. V. Umstead | Chief Financial Officer | 2024-01-04 | 111 | $2.94 | $326.56Sell |
| Mark Avagliano | Chief Business Officer | 2024-01-03 | 2,602 | $3.12 | $8.12kSell |
| Mark Avagliano | Chief Business Officer | 2024-01-03 | 758 | $3.12 | $2.36kSell |
| John E. Jack Bailey Jr. | President and CEO | 2024-01-03 | 9,094 | $3.12 | $28.36kSell |
GTHX insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when GTHX insiders and whales buy or sell their stock.
GTHX Shareholders
What type of owners hold G1 Therapeutics Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Clay Thorp | 14.20% | 7,411,440 | $29.57M | Insider |
| Ra Capital Management LP | 9.52% | 4,968,488 | $19.82M | Insider |
| Fredric N. Eshelman | 7.07% | 3,689,151 | $14.72M | Insider |
| Eshelman Ventures LLC | 6.59% | 3,439,151 | $13.72M | Insider |
| Medimmune Ventures Inc | 5.65% | 2,950,630 | $11.77M | Insider |
| Vanguard Group Inc | 3.80% | 1,981,673 | $7.91M | Institution |
| Susquehanna International Group LLP | 3.02% | 1,578,601 | $6.30M | Institution |
| Blackrock Inc | 1.30% | 680,664 | $2.72M | Institution |
| Renaissance Technologies LLC | 1.21% | 630,400 | $2.52M | Institution |
| Raymond James Associates | 1.08% | 565,555 | $2.26M | Institution |
GTHX vs Biotech Stocks
G1 Therapeutics Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.